Pogany G, Raso E, Peterszegi G, Keresztfalvi M, Lapis K, Jeney A
Joint Research Organization of the Hungarian Academy of Sciences and Semmelweis Medical University, Department of Molecular Pathology, Budapest.
Anticancer Res. 1992 Jan-Feb;12(1):281-4.
The IMP and GMP concentrations were compared after treatment with tiazofurin alone and in combination with 5-hexyl-2'-deoxyuridine (HUdR) in 3LL-HH adenocarcinoma in vivo. The elevation in IMP/GMP ratio, indicating guanylate depletion and increase of inosine-5'-monophosphate concentration, showed a dose dependence and was the highest at the 7th hour after treatment with tiazofurin. HUdR application alone caused only a modest change in the nucleotide concentration of LL-HH tumour. However, the rise of IMP but not the reduction of guanylate concentration induced by tiazofurin was remarkably mitigated by HUdR treatment, without affecting the antitumour potency of tiazofurin. Thus HUdR showed modifying activity on some of the tiazofurin-induced changes in nucleotide metabolism which appeared not to be associated with the antiproliferative activity of tiazofurin. It follows that reduced GMP concentration and not the elevation of IMP/GMP ratio could predict therapeutic responses to tiazofurin.
在体内对3LL-HH腺癌单独使用硫唑嘌呤以及将其与5-己基-2'-脱氧尿苷(HUdR)联合使用后,比较了IMP和GMP的浓度。IMP/GMP比值升高表明鸟苷酸耗竭且5'-肌苷单磷酸浓度增加,呈现剂量依赖性,并且在用硫唑嘌呤治疗后第7小时最高。单独应用HUdR仅使LL-HH肿瘤的核苷酸浓度发生适度变化。然而,HUdR治疗可显著减轻硫唑嘌呤诱导的IMP升高而非鸟苷酸浓度降低,且不影响硫唑嘌呤的抗肿瘤效力。因此,HUdR对硫唑嘌呤诱导的核苷酸代谢某些变化具有调节活性,而这些变化似乎与硫唑嘌呤的抗增殖活性无关。由此可见,GMP浓度降低而非IMP/GMP比值升高可预测对硫唑嘌呤的治疗反应。